» Articles » PMID: 36363516

Fecal Microbiota Transplantation in NAFLD Treatment

Overview
Publisher MDPI
Specialty General Medicine
Date 2022 Nov 11
PMID 36363516
Authors
Affiliations
Soon will be listed here.
Abstract

: Gut microbiota is not only a taxonomic biologic ecosystem but is also involved in human intestinal and extra-intestinal functions such as immune system modulation, nutrient absorption and digestion, as well as metabolism regulation. The latter is strictly linked to non-alcoholic fatty liver disease (NAFLD) pathophysiology. : We reviewed the literature on the definition of gut microbiota, the concepts of "dysbiosis" and "eubiosis", their role in NAFLD pathogenesis, and the data on fecal microbiota transplantation (FMT) in these patients. We consulted the main medical databases using the following keywords, acronyms, and their associations: gut microbiota, eubiosis, dysbiosis, bile acids, NAFLD, and FMT. : Gut microbiota qualitative and quantitative composition is different in healthy subjects vs. NALFD patients. This dysbiosis is associated with and involved in NAFLD pathogenesis and evolution to non-acoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma (HCC). In detail, microbial-driven metabolism of bile acids (BAs) and interaction with hepatic and intestinal farnesoid nuclear X receptor (FXR) have shown a determinant role in liver fat deposition and the development of fibrosis. Over the use of pre- or probiotics, FMT has shown preclinical and initial clinical promising results in NAFLD treatment through re-modulation of microbial dysbiosis. : Promising clinical data support a larger investigation of gut microbiota dysbiosis reversion through FMT in NAFLD using randomized clinical trials to design precision-medicine treatments for these patients at different disease stages.

Citing Articles

Chaihuang Qingyi Huoxue granule ameliorates severe acute pancreatitis by modulating gut microbiota and repairing the intestinal mucosal barrier.

Zhang X, Zeng X, Guo W, Zhou X, Zhang Y, Tang M Front Cell Infect Microbiol. 2025; 15:1514201.

PMID: 40041150 PMC: 11876134. DOI: 10.3389/fcimb.2025.1514201.


Interactions between Gut Microbiota and Natural Bioactive Polysaccharides in Metabolic Diseases: Review.

Pi Y, Fang M, Li Y, Cai L, Han R, Sun W Nutrients. 2024; 16(17).

PMID: 39275156 PMC: 11397228. DOI: 10.3390/nu16172838.


NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options.

Vallianou N, Kounatidis D, Psallida S, Vythoulkas-Biotis N, Adamou A, Zachariadou T Metabolites. 2024; 14(7).

PMID: 39057689 PMC: 11278747. DOI: 10.3390/metabo14070366.


Bile acid-gut microbiota imbalance in cholestasis and its long-term effect in mice.

Yang X, Xu Y, Li J, Ran X, Gu Z, Song L mSystems. 2024; 9(7):e0012724.

PMID: 38934542 PMC: 11265269. DOI: 10.1128/msystems.00127-24.


A catalog of ethanol-producing microbes in humans.

Mbaye B, Wasfy R, Alou M, Borentain P, Gerolami R, Dufour J Future Microbiol. 2024; 19(8):697-714.

PMID: 38700288 PMC: 11259083. DOI: 10.2217/fmb-2023-0250.


References
1.
Bifari F, Manfrini R, Cas M, Berra C, Siano M, Zuin M . Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacol Res. 2018; 137:219-229. DOI: 10.1016/j.phrs.2018.09.025. View

2.
Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R . Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. J Pediatr Gastroenterol Nutr. 2017; 64(3):413-417. DOI: 10.1097/MPG.0000000000001422. View

3.
Aller R, de Luis D, Izaola O, Conde R, Gonzalez Sagrado M, Primo D . Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011; 15(9):1090-5. View

4.
Stofan M, Guo G . Bile Acids and FXR: Novel Targets for Liver Diseases. Front Med (Lausanne). 2020; 7:544. PMC: 7516013. DOI: 10.3389/fmed.2020.00544. View

5.
Younossi Z, Golabi P, de Avila L, Paik J, Srishord M, Fukui N . The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019; 71(4):793-801. DOI: 10.1016/j.jhep.2019.06.021. View